Botanix Pharmaceuticals Ltd (BOT) - Total Liabilities
Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) has total liabilities worth AU$47.80 Million AUD (≈ $33.82 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Botanix Pharmaceuticals Ltd - Total Liabilities Trend (1989–2025)
This chart illustrates how Botanix Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. See Botanix Pharmaceuticals Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Botanix Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Botanix Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Petrolia SE
F:0PE
|
Germany | €27.62 Million |
|
Eldav-L
TA:ELDAV
|
Israel | ILA2.41 Million |
|
BIONXT SOLUTIONS INC.
F:BXT
|
Germany | €9.54 Million |
|
Averbuch Formica Center Ltd
TA:AVER
|
Israel | ILA30.26 Million |
|
ML System S.A.
WAR:MLS
|
Poland | zł393.10 Million |
|
Drax Group PLC
LSE:DRX
|
UK | GBX3.27 Billion |
|
Stakeholder Gold Corp
V:SRC
|
Canada | CA$384.54K |
|
Net Digital AG
XETRA:VRL
|
Germany | €7.85 Million |
Liability Composition Analysis (1989–2025)
This chart breaks down Botanix Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BOT market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Botanix Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Botanix Pharmaceuticals Ltd (1989–2025)
The table below shows the annual total liabilities of Botanix Pharmaceuticals Ltd from 1989 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$47.80 Million ≈ $33.82 Million |
+1180.69% |
| 2024-06-30 | AU$3.73 Million ≈ $2.64 Million |
+97.99% |
| 2023-06-30 | AU$1.88 Million ≈ $1.33 Million |
-67.97% |
| 2022-06-30 | AU$5.89 Million ≈ $4.16 Million |
+411.76% |
| 2021-06-30 | AU$1.15 Million ≈ $813.76K |
-31.31% |
| 2020-06-30 | AU$1.67 Million ≈ $1.18 Million |
-63.48% |
| 2019-06-30 | AU$4.58 Million ≈ $3.24 Million |
+221.60% |
| 2018-06-30 | AU$1.43 Million ≈ $1.01 Million |
+202.93% |
| 2017-06-30 | AU$470.60K ≈ $332.98K |
-8.77% |
| 2016-06-30 | AU$515.83K ≈ $364.98K |
+463.23% |
| 2015-06-30 | AU$91.58K ≈ $64.80K |
-70.44% |
| 2014-06-30 | AU$309.85K ≈ $219.24K |
-87.65% |
| 2013-06-30 | AU$2.51 Million ≈ $1.78 Million |
+6.71% |
| 2012-06-30 | AU$2.35 Million ≈ $1.66 Million |
+3.42% |
| 2011-06-30 | AU$2.27 Million ≈ $1.61 Million |
+22.57% |
| 2010-06-30 | AU$1.86 Million ≈ $1.31 Million |
+62.88% |
| 2009-06-30 | AU$1.14 Million ≈ $805.90K |
+5.28% |
| 2008-06-30 | AU$1.08 Million ≈ $765.47K |
+79.27% |
| 2007-06-30 | AU$603.47K ≈ $427.00K |
+112.57% |
| 2006-06-30 | AU$283.89K ≈ $200.87K |
+27.17% |
| 2005-06-30 | AU$223.25K ≈ $157.96K |
+22.92% |
| 2004-06-30 | AU$181.62K ≈ $128.50K |
-37.22% |
| 2003-06-30 | AU$289.29K ≈ $204.69K |
-36.82% |
| 2002-06-30 | AU$457.88K ≈ $323.98K |
+170.40% |
| 2001-06-30 | AU$169.34K ≈ $119.82K |
+43.51% |
| 2000-06-30 | AU$118.00K ≈ $83.49K |
-98.54% |
| 1999-06-30 | AU$8.06 Million ≈ $5.71 Million |
-44.80% |
| 1998-06-30 | AU$14.61 Million ≈ $10.34 Million |
-19.80% |
| 1997-06-30 | AU$18.22 Million ≈ $12.89 Million |
-4.79% |
| 1996-06-30 | AU$19.13 Million ≈ $13.54 Million |
-35.62% |
| 1995-06-30 | AU$29.72 Million ≈ $21.03 Million |
+31.96% |
| 1994-06-30 | AU$22.52 Million ≈ $15.94 Million |
+14.41% |
| 1993-06-30 | AU$19.68 Million ≈ $13.93 Million |
+35.61% |
| 1992-06-30 | AU$14.52 Million ≈ $10.27 Million |
-0.16% |
| 1991-06-30 | AU$14.54 Million ≈ $10.29 Million |
+6.72% |
| 1990-06-30 | AU$13.62 Million ≈ $9.64 Million |
+15.26% |
| 1989-06-30 | AU$11.82 Million ≈ $8.36 Million |
-- |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more